Quick Answer
RedHill Biopharma Ltd. reported Gross Profit of $4.85 million for fiscal year 2024.
RedHill Biopharma Ltd. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $4.85M | +58.0% |
| 2023 | $3.07M | -89.2% |
| 2022 | $28.46M | -21.7% |
| 2021 | $36.35M | +32.3% |
| 2020 | $27.47M | +581.2% |
| 2019 | $4.03M | -27.0% |
| 2018 | $5.52M | +193.6% |
| 2017 | $1.88M | +1762.4% |
| 2016 | $101.0K | +3266.7% |
| 2015 | $3.0K | — |
- RedHill Biopharma Ltd. showed an increase of +58.0% in Gross Profit compared to the prior fiscal year.
- Over the 2015–2024 period, RedHill Biopharma Ltd.’s gross profit has grown by 161600.0% (from $3.0 thousand to $4.85 million).
- The most recent figure is from RedHill Biopharma Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: